These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33718174)

  • 21. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
    Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
    Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.
    Cappelli LC; Gutierrez AK; Baer AN; Albayda J; Manno RL; Haque U; Lipson EJ; Bleich KB; Shah AA; Naidoo J; Brahmer JR; Le D; Bingham CO
    Ann Rheum Dis; 2017 Jan; 76(1):43-50. PubMed ID: 27307501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities.
    Furudate S; Fujimura T; Kambayashi Y; Hidaka T; Hashimoto A; Aiba S
    Case Rep Oncol; 2016; 9(3):644-649. PubMed ID: 27920696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associated Myocarditis: A Predictive Factor for Response?
    Shalata W; Peled N; Gabizon I; Abu Saleh O; Kian W; Yakobson A
    Case Rep Oncol; 2020; 13(2):550-557. PubMed ID: 32518552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
    Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
    J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy.
    Kambayashi Y; Fujimura T; Kuroda H; Otsuka A; Irie H; Aiba S
    Case Rep Oncol; 2020; 13(1):474-477. PubMed ID: 32508619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma.
    Spain L; Larkin J
    Expert Opin Biol Ther; 2016; 16(3):389-96. PubMed ID: 26750801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Papillary cystadenocarcinoma originating from a minor salivary gland with lymph node metastases.
    Etit D; Ekinci N; Evcim G; Onal K
    Ear Nose Throat J; 2011 Mar; 90(3):E6-7. PubMed ID: 21412732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytology of low-grade cribriform cystadenocarcinoma in salivary glands: Cytological and immunohistochemical distinctions from other salivary gland neoplasms.
    Ohta Y; Hirota Y; Kohno Y; Kishimoto K; Norose T; Ohike N; Takimoto M; Shiokawa A; Ota H
    Diagn Cytopathol; 2016 Mar; 44(3):241-5. PubMed ID: 26875597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nivolumab for the treatment of unresectable pleural mesothelioma.
    Hotta K; Fujimoto N; Kozuki T; Aoe K; Kiura K
    Expert Opin Biol Ther; 2020 Feb; 20(2):109-114. PubMed ID: 31825692
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
    Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
    Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab.
    Olson DJ; Rajagopal P; Tjota MY; Venkataraman G; Luke JJ; Gajewski TF
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy.
    Pires da Silva I; Lo S; Quek C; Gonzalez M; Carlino MS; Long GV; Menzies AM
    Cancer; 2020 Jan; 126(1):86-97. PubMed ID: 31584722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ipilimumab/nivolumab-induced pseudolymphoma in a patient with malignant melanoma.
    Ayoubi N; Haque A; Vera N; Ma S; Messina J; Khushalani N; Seminario-Vidal L
    J Cutan Pathol; 2020 Apr; 47(4):390-393. PubMed ID: 31677178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
    Gao CA; Weber UM; Peixoto AJ; Weiss SA
    J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials.
    Menshawy A; Eltonob AA; Barkat SA; Ghanem A; Mniesy MM; Mohamed I; Abdel-Maboud M; Mattar OM; Elfil M; Bahbah EI; Elgebaly A
    Melanoma Res; 2018 Oct; 28(5):371-379. PubMed ID: 29957656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
    Hantel A; Gabster B; Cheng JX; Golomb H; Gajewski TF
    J Immunother Cancer; 2018 Jul; 6(1):73. PubMed ID: 30012206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
    Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
    J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cystadenocarcinoma (papillary cystadenocarcinoma) of the submandibular gland.
    Harimaya A; Somekawa Y; Sasaki M; Ohuchi T
    J Laryngol Otol; 2006 Dec; 120(12):1077-80. PubMed ID: 16995970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.